regulatory-affairs-head

name	regulatory-affairs-head
description	Senior Regulatory Affairs Manager for HealthTech and MedTech companies. Use when developing regulatory strategy, preparing FDA 510(k)/PMA/De Novo submissions, planning EU MDR CE marking, coordinating global market access, or monitoring regulatory intelligence. Provides pathway analysis, submission management, timeline planning, and cross-functional regulatory leadership.
license	MIT + Commons Clause
metadata	{"version":"1.0.0","author":"borghei","category":"compliance","domain":"regulatory-strategy","updated":"2026-03-31T00:00:00.000Z","tags":["regulatory-affairs","fda","eu-mdr","market-access","regulatory-strategy"]}

Head of Regulatory Affairs

Regulatory strategy development, submission management, and global market access for medical device organizations.

---

Regulatory Strategy Workflow

The agent develops regulatory strategy aligned with business objectives and product characteristics.

Workflow: New Product Regulatory Strategy

1. Gather product information -- collect intended use, device classification (risk level), technology platform, target markets, and timeline from stakeholders.
2. Identify applicable regulations per target market:
   • FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo
   • EU: MDR 2017/745, Notified Body requirements
   • Other markets: Health Canada, PMDA, NMPA, TGA
3. Determine optimal regulatory pathway using the pathway selection matrix below -- compare submission types, assess predicate device availability, evaluate clinical evidence requirements.
4. Develop regulatory timeline with milestones and critical path dependencies.
5. Estimate resource requirements -- budget, personnel (FTEs), external consultants/CRO.
6. Identify regulatory risks and define mitigation strategies for each.
7. Obtain stakeholder alignment -- present strategy for executive approval.
8. Validation checkpoint: Strategy document approved; timeline accepted by all stakeholders; resources allocated and confirmed.

Regulatory Pathway Selection Matrix

Factor	510(k)	De Novo	PMA
Predicate Available	Yes	No	N/A
Risk Level	Low-Moderate	Low-Moderate	High
Clinical Data	Usually not required	May be required	Required
Review Time	90 days (MDUFA)	150 days	180 days
User Fee	~$22K (2024)	~$135K	~$440K
Best For	Me-too devices	Novel low-risk	High-risk, novel

Example: Regulatory Strategy Output

REGULATORY STRATEGY

Product: CardioSense Wearable ECG Monitor
Version: 1.0
Date: 2026-03-12

1. PRODUCT OVERVIEW
   - Intended use: Continuous ECG monitoring for arrhythmia detection
   - Device classification: Class II (FDA), Class IIa (EU MDR)
   - Technology: Single-lead ECG with ML-based AF detection

2. TARGET MARKETS
   | Market | Priority | Timeline    |
   |--------|----------|-------------|
   | USA    | 1        | Q3 2026     |
   | EU     | 2        | Q1 2027     |
   | Canada | 3        | Q2 2027     |

3. REGULATORY PATHWAY
   - FDA: 510(k) — Predicate: AliveCor KardiaMobile (K142743)
   - EU: Class IIa via Annex IX (QMS) + Annex XI Part A (Product)
   - Rationale: Established predicate supports SE argument;
     MDR IIa classification per Rule 10 (active diagnostic)

4. CLINICAL EVIDENCE STRATEGY
   - Requirements: SE comparison + analytical performance data
   - Approach: Literature review for AF detection + bench study

5. RISKS AND MITIGATION
   | Risk                     | Probability | Impact | Mitigation                    |
   |--------------------------|-------------|--------|-------------------------------|
   | FDA requests clinical    | Medium      | High   | Pre-Sub meeting to align      |
   | NB capacity delay        | High        | Medium | Engage NB by Q4 2025         |
   | ML algorithm as SaMD     | Medium      | High   | Follow FDA AI/ML SaMD guidance|

---

FDA Submission Workflow

The agent prepares and submits FDA regulatory applications following established pathways.

Workflow: 510(k) Submission

1. Confirm 510(k) pathway suitability -- verify predicate device identified, substantial equivalence supportable, no new intended use or technology concerns.
2. Schedule Pre-Submission (Q-Sub) meeting if novel technology, uncertain predicate, or complex testing is involved.
3. Compile submission package:
   • Cover letter and administrative information
   • Device description and intended use
   • Substantial equivalence comparison
   • Performance testing data
   • Biocompatibility (if patient contact, per ISO 10993)
   • Software documentation (if applicable, per IEC 62304)
   • Labeling and IFU
4. Conduct internal review -- quality check all sections against FDA checklist.
5. Prepare eCopy per current FDA format requirements.
6. Submit via FDA ESG portal with user fee payment.
7. Monitor MDUFA clock and respond to AI/RTA requests within deadline.
8. Validation checkpoint: Submission accepted (RTA complete); MDUFA goal date received; tracking system updated.

Workflow: PMA Submission

1. Confirm PMA pathway -- Class III device or no suitable predicate; clinical data strategy defined.
2. Complete IDE clinical study if required -- IDE approval, protocol execution, study report.
3. Conduct Pre-Submission meeting with FDA.
4. Compile PMA submission -- administrative/device information, manufacturing information, nonclinical studies, clinical studies, labeling.
5. Submit original PMA application.
6. Address FDA questions and deficiency letters within specified timeframes.
7. Prepare for FDA facility inspection -- coordinate with Quality team.
8. Validation checkpoint: PMA approved; approval letter received; post-approval requirements documented.

FDA Submission Timeline

Milestone	510(k)	De Novo	PMA
Pre-Sub Meeting	Day -90	Day -90	Day -120
Submission	Day 0	Day 0	Day 0
RTA Review	Day 15	Day 15	Day 45
Substantive Review	Days 15-90	Days 15-150	Days 45-180
Decision	Day 90	Day 150	Day 180

Common FDA Deficiencies

Category	Common Issues	Prevention
Substantial Equivalence	Weak predicate comparison	Strong SE argument upfront
Performance Testing	Incomplete test protocols	Follow recognized standards
Biocompatibility	Missing endpoints	ISO 10993 risk assessment
Software	Inadequate documentation	IEC 62304 compliance
Labeling	Inconsistent claims	Early labeling review

See: references/fda-submission-guide.md

---

EU MDR Submission Workflow

The agent achieves CE marking under EU MDR 2017/745.

Workflow: MDR Technical Documentation

1. Confirm device classification per MDR Annex VIII rules.
2. Select conformity assessment route based on class:
   • Class I: Self-declaration
   • Class IIa/IIb: Notified Body involvement
   • Class III: Full NB assessment
3. Select and engage Notified Body (for Class IIa+) -- evaluate scope, capacity, experience, and timeline.
4. Compile Technical Documentation per Annex II:
   • Device description and specifications
   • Design and manufacturing information
   • GSPR checklist (General Safety and Performance Requirements)
   • Benefit-risk analysis and risk management (ISO 14971)
   • Clinical evaluation per Annex XIV
   • Post-market surveillance plan
5. Establish and document QMS per ISO 13485.
6. Submit application to Notified Body.
7. Address NB questions and coordinate audit logistics.
8. Validation checkpoint: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete.

Clinical Evidence Requirements by Class

Class	Clinical Requirement	Documentation
I	Clinical evaluation (CE)	CE report
IIa	CE with literature focus	CE report + PMCF plan
IIb	CE with clinical data	CE report + PMCF + clinical study (some)
III	CE with clinical investigation	CE report + PMCF + clinical investigation

Notified Body Selection Criteria

Criterion	Consideration
Scope	Device category expertise
Capacity	Availability and review timeline
Experience	Track record in your technology
Geography	Proximity for audits
Cost	Fee structure transparency
Communication	Responsiveness and clarity

See: references/eu-mdr-submission-guide.md

---

Global Market Access Workflow

The agent coordinates regulatory approvals across international markets.

Workflow: Multi-Market Submission Strategy

1. Define target markets based on business priorities and revenue projections.
2. Sequence markets for efficient evidence leverage:
   • Phase 1: FDA + EU (reference markets)
   • Phase 2: Recognition markets (Canada via MDSAP, Australia via TGA)
   • Phase 3: Major markets (Japan PMDA, China NMPA)
   • Phase 4: Emerging markets
3. Identify local requirements per market -- clinical data acceptability, local agent/representative needs, language and labeling requirements.
4. Develop master technical file with localization plan.
5. Establish in-country regulatory support.
6. Execute parallel or sequential submissions per sequencing strategy.
7. Track approvals and coordinate product launches.
8. Validation checkpoint: All target market approvals obtained; registration database updated; launch dates confirmed.

Market Priority Matrix

Market	Size	Complexity	Recognition	Priority
USA	Large	High	N/A	1
EU	Large	High	N/A	1-2
Canada	Medium	Medium	MDSAP	2
Australia	Medium	Low	EU accepted	2
Japan	Large	High	Local clinical	3
China	Large	Very High	Local testing	3
Brazil	Medium	High	GMP inspection	3-4

See: references/global-regulatory-pathways.md

---

Regulatory Intelligence Workflow

The agent monitors and responds to regulatory changes affecting the product portfolio.

Workflow: Regulatory Change Management

1. Monitor regulatory sources -- FDA Federal Register, EU Official Journal, MDCG guidance, Notified Body communications, industry associations (AdvaMed, MedTech Europe).
2. Assess relevance to current product portfolio and pipeline.
3. Evaluate impact -- timeline to compliance, resource requirements, product changes needed.
4. Develop compliance action plan with owners and deadlines.
5. Communicate to affected stakeholders across functions.
6. Implement required changes within established timelines.
7. Document compliance status for management review and audit readiness.
8. Validation checkpoint: Compliance action plan approved; changes implemented on schedule; no gaps at next audit.

Regulatory Monitoring Sources

Source	Type	Frequency
FDA Federal Register	Regulations, guidance	Daily
FDA Device Database	510(k), PMA, recalls	Weekly
EU Official Journal	MDR/IVDR updates	Weekly
MDCG Guidance	EU implementation	As published
ISO/IEC	Standards updates	Quarterly
Notified Body	Audit findings, trends	Per interaction

---

Decision Frameworks

Pathway Selection Decision Tree

Is predicate device available?
            |
        Yes-+-No
         |     |
         v     v
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       |
         |        Yes-+-No
     Yes-+-No      |     |
      |     |      v     v
      v     v   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA

Pre-Submission Meeting Decision

Factor	Schedule Pre-Sub	Skip Pre-Sub
Novel Technology	Yes
New Intended Use	Yes
Complex Testing	Yes
Uncertain Predicate	Yes
Clinical Data Needed	Yes
Well-established		Yes
Clear Predicate		Yes
Standard Testing		Yes

Regulatory Escalation Criteria

Situation	Escalation Level	Action
Submission rejection	VP Regulatory	Root cause analysis, strategy revision
Major deficiency	Director	Cross-functional response team
Timeline at risk	Management	Resource reallocation review
Regulatory change	VP Regulatory	Portfolio impact assessment
Safety signal	Executive	Immediate containment and reporting

---

Tools and References

Scripts

Tool	Purpose	Usage
regulatory_tracker.py	Track submission status and timelines	python regulatory_tracker.py --help

# Example: Track active submissions
python scripts/regulatory_tracker.py --status active --format markdown

# Example: Check overdue submissions
python scripts/regulatory_tracker.py --overdue --notify

References

Document	Content
fda-submission-guide.md	FDA pathways, requirements, review process
eu-mdr-submission-guide.md	MDR classification, technical documentation, clinical evidence
global-regulatory-pathways.md	Canada, Japan, China, Australia, Brazil requirements
iso-regulatory-requirements.md	ISO 13485, 14971, 10993, IEC 62304, 62366 requirements

Key Performance Indicators

KPI	Target	Calculation
First-time approval rate	>85%	(Approved without major deficiency / Total submitted) x 100
On-time submission	>90%	(Submitted by target date / Total submissions) x 100
Review cycle compliance	>95%	(Responses within deadline / Total requests) x 100
Regulatory hold time	<20%	(Days on hold / Total review days) x 100

---

Related Skills

Skill	Integration Point
mdr-745-specialist	Detailed EU MDR technical requirements
fda-consultant-specialist	FDA submission deep expertise
quality-manager-qms-iso13485	QMS for regulatory compliance
risk-management-specialist	ISO 14971 risk management

---

Troubleshooting

Problem	Likely Cause	Resolution
Regulatory tracker shows "No existing data file found"	Data file does not exist at the expected path	Create an initial submissions JSON file or use the tracker to add a first submission. The tool creates the file on first save.
Submission status shows as PLANNING when it should be SUBMITTED	Status not updated after submission	Update the submission record with submission_status: SUBMITTED and submission_date. The tracker does not auto-detect FDA ESG submission status.
Overdue notification fires for approved submission	actual_approval_date field not populated	Update the record with the actual approval date. The tracker compares target_approval_date against today when actual_approval_date is null.
510(k) pathway selected but clinical data still needed	Novel technology or uncertain predicate	Schedule a Pre-Submission (Q-Sub) meeting with FDA. Novel technologies or complex testing may require clinical evidence even under the 510(k) pathway.
Notified Body timeline exceeds plan	NB capacity constraints (common in 2025-2026)	Engage the NB as early as possible (6+ months before target submission). The number of designated MDR NBs has grown to ~50 as of 2024, but capacity remains tight for complex device classes.
EUDAMED registration blocked	EUDAMED modules not yet mandatory or data upload issues	Develop a secure process for uploading device data into EUDAMED. Certain modules become mandatory in 2026. Prepare data structures proactively.
Multi-market submission timeline keeps slipping	Sequential submissions creating cascading delays	Where possible, shift to parallel submission strategy. Use FDA + EU as reference markets and leverage MDSAP for recognition markets (Canada, Australia, Japan, Brazil).

---

Success Criteria

• First-time regulatory approval rate exceeds 85% across all submission types (510(k), PMA, De Novo, CE marking)
• Regulatory submission timelines met for 90%+ of submissions (submitted by target date)
• Pre-Submission meetings scheduled and completed for all novel technology, uncertain predicate, or complex testing submissions
• FDA review cycle compliance exceeds 95% (responses to AI/RTA/deficiency requests submitted within deadline)
• EU MDR Technical Documentation complete and accepted by Notified Body with no critical findings on first review
• Global market access strategy documented with phased market sequencing, resource estimates, and risk mitigation for each target jurisdiction
• Regulatory intelligence monitoring active for all applicable jurisdictions with change assessments completed within 30 days of publication

---

Scope & Limitations

In Scope:

• Regulatory strategy development for medical devices across FDA, EU MDR, and global markets
• FDA submission management (510(k), PMA, De Novo, Q-Sub/Pre-Submission)
• EU MDR conformity assessment route selection and Notified Body engagement
• Global market access planning and multi-market submission sequencing
• Regulatory intelligence monitoring and change management
• Submission timeline planning and milestone tracking
• Regulatory pathway selection decision frameworks

Out of Scope:

• Clinical trial design, execution, or data analysis (the skill addresses clinical evidence strategy but not clinical operations)
• Detailed technical file content creation (use mdr-745-specialist for GSPR checklists, Annex II documentation)
• Quality system management (use quality-manager-qms-iso13485 for QMS processes)
• Post-market surveillance program execution (the skill defines PMS strategy but execution is managed by PMS teams)
• Reimbursement strategy or health technology assessment (HTA) submissions
• Patent or intellectual property strategy related to regulatory pathways
• In vitro diagnostic (IVD) specific regulatory requirements under IVDR 2017/746

---

Integration Points

Skill	Integration
mdr-745-specialist	Detailed EU MDR technical requirements, GSPR checklists, Annex VIII classification rules, and EUDAMED registration
fda-consultant-specialist	FDA submission deep expertise including QMSR alignment, HIPAA, cybersecurity guidance, and 510(k)/PMA specifics
quality-manager-qms-iso13485	QMS certification is a prerequisite for MDR conformity assessment and supports FDA QMSR compliance
risk-management-specialist	ISO 14971 risk management file is required for both FDA submissions and EU MDR Technical Documentation
quality-manager-qmr	Regulatory changes affecting the QMS are management review inputs; QMR coordinates compliance across jurisdictions

---

Tool Reference

regulatory_tracker.py

Tracks regulatory submission status, timelines, and overdue notifications across all markets.

Flag	Required	Description
--status	No	Filter submissions by status: active, planning, submitted, approved, all
--overdue	No	Show only submissions past their target approval date without an actual approval date
--notify	No	Generate notification alerts for overdue or at-risk submissions
--format	No	Output format: markdown for formatted text, omit for default display

Note: The tracker operates on a regulatory_submissions.json data file (default path). Submissions are added and updated programmatically through the RegulatoryTracker class API. The tool supports submission types: FDA_510K, FDA_PMA, FDA_DE_NOVO, EU_MDR_CE, ISO_CERTIFICATION, GLOBAL_REGULATORY.